TRPV1, a Novel Biomarker Associated with Lung Cancer Via Excluding Immune Infiltration

Rui Gao,Mei Meng,Xianchao Zhou,Miao Yu,Zhifan Li,Jingquan Li,Xiaonan Wang,Yizhi Song,Hui Wang,Jian He

DOI: https://doi.org/10.1002/mco2.139

2022-01-01

MedComm

Abstract:Dear Editor, Lung cancer is one of the most common malignant tumors worldwide, and its metastasis is a key biological process causing poor prognosis. In the past two decades, lung adenocarcinoma (LUAD) has been referred to as a type of nonimmunogenic cancer.1 However, alongwith the increasing understanding of tumor-immune interactions, this model in lung cancer was questioned.2 The mechanisms of immune-related interaction play key roles in the genesis and development of tumors, and immunotherapy is considered to be a promising approach for cancer therapeutics.3 Note that 2021 Medicine Nobel went to scientists who discovered the biology of TRPV1, which helps researchers to understand the molecular basis for pain.4 But few research has elucidated the role of TRPV1 inmalignancies, especially the correlations of TRPV1 to the prognoses and tumor-infiltrating lymphocytes (TILs) in different cancers remain poorly described.5 Here, we aimed to assess TRPV1 as well as a potential prognostic biomarker and to explore its possibility to become a novel therapeutic target in lung cancer. Firstly, we analyzed the levels of TRPV1 mRNA expression using the online RNA-Seq datasets of multiple tumor types. Compared to the paired adjacent normal tissues, the mRNA expression level of TRPV1 in the tumor tissues of LUAD and LUSCwas significantly higher (Figure 1A). Secondly, we investigated whether TRPV1 mRNA expression level was associated with the prognosis. It is shown that the higher the expression level of TRPV1, the worse the prognosis (Figure 1B). Therefore, we believe that the high expression level of TRPV1 mRNA is an independent risk factor for poor prognosis in lung cancer patient cohorts, and HR higher than 1 indicates that the mRNA expression of this gene could be a risk factor. Meanwhile, the different prognosis patterns between LUAD and LUSC caught our attention (Figure 1C,D). These statistical results indicated the prognostic potential of TRPV1 in lung cancer, and the difference in TRPV1 expression leads to different prognostic potential patterns in different subtypes of lung cancer.